Global Monkeypox Treatment Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Monkeypox Treatment Market Research Report 2024
Monkeypox (mpox) is a viral infection that spreads from animals to humans, hence it is called a zoonotic infection. The recent outbreak of mpox on May 6, 2022. The human mpox virus was initially identified in 1970 in the Democratic Republic of Congo. The source of the virus is unknown; however, the first six monkeypox cases were found in the UK. Fever, swelling in the lymph nodes, rashes on the skin, chills, muscle fatigue, headache, backache, and respiratory symptoms such as sore throat, cough, and congestion are the common symptoms of monkeypox infection. The virus is transmitted sexually or through touch. The disease has claimed the lives of some people. People with weak immunity, breastfeeding mothers, women during pregnancy, children below the age of 10 years, and people having prolonged exposure to the infected animal are susceptible to the viral infection.
According to MRAResearch’s new survey, global Monkeypox Treatment market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Monkeypox Treatment market research.
Key companies engaged in the Monkeypox Treatment industry include Bavarian Nordic, Chimerix, Inc., CIDIC Company Limited, Emcure Pharmaceuticals, Emergent, Gilead Sciences Inc., Hetero Drugs Limited, Jinan Jinda Pharmaceutical Chemistry Co. Ltd. and Mylan N.V., etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Monkeypox Treatment were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Monkeypox Treatment market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Monkeypox Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Bavarian Nordic
Chimerix, Inc.
CIDIC Company Limited
Emcure Pharmaceuticals
Emergent
Gilead Sciences Inc.
Hetero Drugs Limited
Jinan Jinda Pharmaceutical Chemistry Co. Ltd.
Mylan N.V.
Olon S.p.A.
Piramal Pharma Solutions
SIGA Technologies Inc.
Sonofi SA
Teva Pharmaceutical Industries Limited
Segment by Type
Oral
Injectable
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Monkeypox Treatment report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Monkeypox Treatment market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Monkeypox Treatment market research.
Key companies engaged in the Monkeypox Treatment industry include Bavarian Nordic, Chimerix, Inc., CIDIC Company Limited, Emcure Pharmaceuticals, Emergent, Gilead Sciences Inc., Hetero Drugs Limited, Jinan Jinda Pharmaceutical Chemistry Co. Ltd. and Mylan N.V., etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Monkeypox Treatment were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Monkeypox Treatment market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Monkeypox Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Bavarian Nordic
Chimerix, Inc.
CIDIC Company Limited
Emcure Pharmaceuticals
Emergent
Gilead Sciences Inc.
Hetero Drugs Limited
Jinan Jinda Pharmaceutical Chemistry Co. Ltd.
Mylan N.V.
Olon S.p.A.
Piramal Pharma Solutions
SIGA Technologies Inc.
Sonofi SA
Teva Pharmaceutical Industries Limited
Segment by Type
Oral
Injectable
Segment by Application
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Monkeypox Treatment report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source